Integer Holdings Co. (NYSE:ITGR) Receives $120.50 Average Target Price from Analysts

Integer Holdings Co. (NYSE:ITGR) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $120.50.

ITGR has been the subject of a number of recent research reports. Benchmark upped their price objective on shares of Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. Bank of America raised Integer from a “neutral” rating to a “buy” rating and raised their price objective for the company from $105.00 to $135.00 in a research note on Monday, April 15th. KeyCorp upped their target price on Integer from $123.00 to $139.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 9th. Finally, CL King began coverage on shares of Integer in a research note on Thursday, March 14th. They issued a “buy” rating and a $137.00 price objective for the company.

Integer Price Performance

Shares of NYSE:ITGR opened at $117.92 on Friday. The firm has a market cap of $3.95 billion, a price-to-earnings ratio of 43.84, a P/E/G ratio of 1.61 and a beta of 1.10. Integer has a 1 year low of $69.40 and a 1 year high of $121.53. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64. The business has a fifty day simple moving average of $112.31 and a 200 day simple moving average of $99.32.

Integer (NYSE:ITGR) last posted its quarterly earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.05. The company had revenue of $413.15 million during the quarter, compared to the consensus estimate of $409.04 million. Integer had a return on equity of 10.80% and a net margin of 5.68%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the business earned $1.11 EPS. As a group, sell-side analysts predict that Integer will post 5.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integer

Hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP acquired a new position in Integer during the 3rd quarter valued at $816,000. Dark Forest Capital Management LP raised its position in shares of Integer by 69.8% during the third quarter. Dark Forest Capital Management LP now owns 11,984 shares of the medical equipment provider’s stock valued at $940,000 after buying an additional 4,926 shares during the last quarter. Legacy Wealth Asset Management LLC bought a new stake in shares of Integer in the fourth quarter valued at about $239,000. Nomura Holdings Inc. grew its position in Integer by 3.9% during the third quarter. Nomura Holdings Inc. now owns 180,270 shares of the medical equipment provider’s stock worth $14,139,000 after buying an additional 6,731 shares in the last quarter. Finally, Trust Point Inc. bought a new position in Integer during the fourth quarter valued at about $874,000. 99.29% of the stock is owned by institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.